Amylyx Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 384
- Market Cap
- $145M
- Website
- http://www.amylyx.com
Open Label Extension Study of AMX0035 in Patients With ALS
Phase 2
Completed
- Conditions
- Amyotrophic Lateral SclerosisALS
- Interventions
- Drug: AMX0035
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03488524
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2
Completed
- Conditions
- Amyotrophic Lateral SclerosisSpinal Cord DiseasesNervous System DiseasesMotor Neuron DiseaseNeuromuscular DiseasesNeurodegenerative DiseasesTDP-43 ProteinopathiesCentral Nervous System Diseases
- Interventions
- Drug: AMX0035Other: Placebo
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT03127514
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Texas Neurology, P.A., Dallas, Texas, United States
🇺🇸The Penn Comprehensive ALS Center, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath